Trial Profile
Randomized phase III study comparing erlotinib plus bevacizumab to erlotinib alone in patients with previously untreated non-small cell lung cancer harboring EGFR mutation (NEJ026)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Jun 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 May 2020 Results of meta-analysis of randomized trials (ARTEMIS, NEJ026, J025667, Stinchcombe et al, RELAY) comparing VEGF inhibitor plus erlotinib with erlotinib alone in first line treatment for advanced NSCLC harbouring EGFR mutation presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 10 Sep 2019 Results assessing plasma EGFR mutations as preplanned analysis, presented at the 20th World Conference on Lung Cancer